文献速递头颈外科咽喉与嗓音

新辅助化疗联合经口机器人手术治疗局部晚期喉咽癌的疗效

Treatment outcomes of neoadjuvant chemotherapy and transoral robotic surgery in locoregionally advanced laryngopharyngeal carcinoma.
PubMed 文献 · Head Neck · 2021-08-06

本研究纳入50例局部晚期(T3-4或N2-3)头颈癌患者,评估新辅助化疗(NACT)联合经口机器人手术(TORS)的疗效。术后病理切缘阳性2例(4%),阴性48例(96%);39例(78%)无转移淋巴结。全组3年无复发生存率(RFS)为85.4%,多因素分析显示淋巴血管侵犯与RFS显著相关。结论认为该联合方案在局部晚期头颈癌中取得良好的肿瘤学和功能结局。

要点

  • NACT联合TORS在局部晚期头颈癌中3年RFS达85.4%。
  • 术后切缘阴性率96%,78%患者无病理转移淋巴结。
  • 淋巴血管侵犯是多因素分析中与RFS显著相关的因素。

核心结论

  • 在局部晚期头颈癌患者中,NACT联合TORS取得良好的肿瘤学和功能结局。

研究设计与样本

  • 研究纳入50例局部晚期(T3-4或N2-3)头颈癌患者。
  • 原文未报告研究设计类型(如回顾性还是前瞻性)。

主要发现

  • 临床T分期:T1 7例,T2 19例,T3 22例,T4 2例。
  • 临床N分期:N0 9例,N1 18例,N2 22例,N3 1例。
  • 原发灶完全缓解25例(50%),部分缓解25例(50%)。
  • 术后病理切缘阳性2例(4%),阴性48例(96%)。
  • 病理淋巴结:无转移39例(78%),1枚转移11例(22%)。

关键数值与推荐

  • 全组3年无复发生存率(RFS)为85.4%。
  • 多因素分析显示淋巴血管侵犯与RFS显著相关。

临床怎么用

  • 对于局部晚期头颈癌,可考虑NACT联合TORS作为治疗选择之一。
  • 术后应关注淋巴血管侵犯状态以评估复发风险。

局限性

  • 样本量较小(50例),原文未报告随访时长及研究设计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to identify the optimal indications of neoadjuvant chemotherapy (NACT) and transoral robotic surgery (TORS) in patients with locoregionally advanced (T3-4 or N2-3) head and neck cancer (HNC). METHODS: A total of 50 patients were included in the study. RESULTS: T1 was identified in seven cases, T2 in 19, T3 in 22, and T4 in 2. N0 was identified in nine cases, N1 in 18, N2 in 22, and N3 in 1. There were 25 patients (50%) with complete remission of the primary lesion and 25 patients (50%) with partial remission. On pathologic examination of surgical specimens after neoadjuvant chemotherapy and TORS, 2 patients (4%) had a positive surgical margin, and 48 patients (96%) had a negative margin. Pathologic metastatic lymph nodes (LNs) were not observed in 39 cases (78%), and one metastatic LN was observed in 11 cases (22%). The 3-year recurrence-free survival (RFS) of all patients was 85.4%. On multivariate analysis, lymphovascular invasion showed a significant correlation with RFS. CONCLUSIONS: In patients with locoregionally advanced HNC, NACT and TORS achieved favorable oncologic and functional outcomes.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Solimeno LS, Park YM, Lim JY, et al. Treatment outcomes of neoadjuvant chemotherapy and transoral robotic surgery in locoregionally advanced laryngopharyngeal carcinoma. Head Neck. 2021. PMID: 34355819. doi:10.1002/hed.26838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。